Stockreport

Zymeworks Approaching A Moment Of Truth With Zanidatamab [Seeking Alpha]

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF Follow Play 10min Summary ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US a [Read more]